Abortion drug safety review will be completed by March, US FDA says
By Daniel Wiessner Oct 8 (Reuters) - The Trump administration plans to complete a review of the abortion drug mifepristone by March 2027, according to a court filing, paving the way for potential changes that could limit access to the pills.